Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.04 | -0.17 | -0.00 | 0.06 |
| FCF Yield | -0.20% | 5.58% | 8.09% | 2.12% |
| EV / EBITDA | 169.31 | 14.21 | 12.25 | 126.52 |
| Quality | ||||
| ROIC | -0.76% | 9.14% | 12.40% | -0.54% |
| Gross Margin | 50.56% | 102.52% | 83.01% | 58.33% |
| Cash Conversion Ratio | -0.45 | 0.82 | 1.31 | -2.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 41.28% | 42.81% | 35.22% | 15.01% |
| Free Cash Flow Growth | -102.92% | -39.65% | 502.22% | 15.59% |
| Safety | ||||
| Net Debt / EBITDA | -9.90 | -0.59 | -0.56 | -8.55 |
| Interest Coverage | 0.00 | 1,168.45 | 0.00 | 1.74 |
| Efficiency | ||||
| Inventory Turnover | 2.07 | -0.24 | 1.67 | 1.44 |
| Cash Conversion Cycle | 42.37 | -107.76 | 12.62 | 75.95 |